A small cohort study found no association between baseline levels of VEGF-A and sVEGFR2 and clinical outcomes in advanced ccRCC patients treated with pembrolizumab plus axitinib [77]. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.